Affimed/AFMD

$5.75

-2.7%
-
1D1W1MYTD1YMAX

About Affimed

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Ticker

AFMD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adi Hoess

Employees

76

Headquarters

Mannheim, Germany

Affimed Metrics

BasicAdvanced
$89.99M
Market cap
-
P/E ratio
-$7.61
EPS
2.06
Beta
-
Dividend rate
$89.99M
2.05837
$11.10
$2.24
91.78K
3.25
3.232
22.452
33.475
-132.01%
-71.18%
-100.55%
-89.36%
10.141
1.424
1.452
-79.99%
-17.98%
-33.67%

What the Analysts think about Affimed

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 6 analysts.
288.87% upside
High $59.61
Low $4.96
$5.75
Current price
$22.36
Average price target

Affimed Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,050% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€400K
-78.95%
Net income
€-20.2M
-16.87%
Profit margin
-5,050%
294.86%

Affimed Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-€2.10
-€2.00
-€1.60
-€1.35
-
Expected
-€1.96
-€1.89
-€1.84
-€1.54
-€1.57
Surprise
7.4%
5.62%
-13.26%
-12.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Affimed stock?

Affimed (AFMD) has a market cap of $89.99M as of April 14, 2024.

What is the P/E ratio for Affimed stock?

The price to earnings (P/E) ratio for Affimed (AFMD) stock is 0 as of April 14, 2024.

Does Affimed stock pay dividends?

No, Affimed (AFMD) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Affimed dividend payment date?

Affimed (AFMD) stock does not pay dividends to its shareholders.

What is the beta indicator for Affimed?

Affimed (AFMD) has a beta rating of 2.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Affimed stock price target?

The target price for Affimed (AFMD) stock is $22.36, which is 288.87% above the current price of $5.75. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Affimed stock

Buy or sell Affimed stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing